# US 2017/0253593 A1 · Inhibitors of the fibroblast growth factor receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253593 A1
- Document ID: US20170253593A1
- Status: Published application
- Kind: A1
- Application number: 15/599,006
- Filed: 2017-05-18
- Published: 2017-09-07
- Earliest claimed: 2014-01-15
- Assignees: Blueprint Medicines Corporation
- Applicants: Blueprint Medicines Corporation
- Inventors: Neil Bifulco, JR.; Lucian V. DiPietro; Chandrasekhar V. Miduturu
- Web page: https://patentgrep.com/patent/US20170253593A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61P 35/00: Antineoplastic agents
- C07D 217/14: other than aralkyl radicals
- C07D 217/16: substituted by oxygen atoms
- C07D 239/74: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 487/04: Ortho-condensed systems
- C07D 487/14: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.

## Claims

### Claim 1

A compound of Formula Ib, or a pharmaceutically acceptable salt thereof:
wherein:
Warhead is a moiety capable of forming a covalent bond with a nucleophile;
Ring A is a 5-8 membered aryl, 5-12 membered heteroaryl, 3-7 member monocyclic or bicyclic heterocyclyl; or 3-12 membered monocyclic or bicyclic cycloalkyl group;
X is CH;
R4 is H, C1-6 alkyl, or 3-12 membered cycloalkyl;
each of R1 and R2 is, independently, halo, cyano, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, hydroxy, oxo, amino, amido, alkyl urea, optionally substituted 3-7 member heterocyclyl;
R7 is hydrogen or C1-6 alkyl; or R7 together with Ring A forms a 8-12 membered bicyclic heterocyclyl optionally substituted with 1-5 occurrences of R1;
m is 0-5; and
n is 0-5.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Ring A is phenyl substituted with 0-3 R1.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R7 is hydrogen.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R7 together with Ring A form an optionally substituted 8-12 membered bicyclic heterocyclyl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein m is at least 1 and R1 is selected from the group consisting of halo, optionally substituted C1-6 alkyl, and optionally substituted C1-6 alkoxy.

### Claim 6 (depends on 1)

The compound of claim 1, wherein n is 4, with two R2 being halo and two R2 being alkoxy.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the warhead moiety is selected from the group consisting of
wherein each of Ra, Rb, and Rc is, independently, hydrogen, optionally substituted C1-4 alkyl, optionally substituted 3-12 membered cycloalkyl, or cyano.

### Claim 8 (depends on 7)

The compound of claim 7, wherein the warhead moiety is

### Claim 9 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier, or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

A method for treating a condition mediated by FGFR-4, comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

### Claim 11 (depends on 1)

A method for treating a condition characterized by overexpression of FGFR-4, comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

### Claim 12 (depends on 1)

A method for treating a condition characterized by amplified FGF-19, comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

### Claim 13 (depends on 1)

A method for treating a condition characterized by overexpression of FGF-19, comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

### Claim 14 (depends on 1)

A method of treating cancer, the method comprising administering to a subject a therapeutically effective amount of compound of claim 1, wherein the cancer is selected from the group consisting of liver cancer, breast cancer, lung cancer, ovarian cancer, or a sarcoma.

### Claim 15 (depends on 1)

A method of treating hepatocellular carcinoma, the method comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

### Claim 16 (depends on 1)

A method of treating hyperlipidemia, the method comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

### Claim 17

A compound selected from any one of the following:
Compound
Number
Structure
4
9
10
12
17
19
20
21
23
25
26
27
35
37
39
40
41
42
43
45
47
49
51
52
53
54
